Reltecimod (AB-103) TFA is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod TFA has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod TFA modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod TFA can be used to research necrotizing soft-tissue infections (NSTIs)[1].
Molecular Weight:
1037.19 (free base)
Purity:
99.78
Formula:
C46H72N10O15S.xC2HF3O2
Target:
Bacterial,CD28
Application Notes:
Peptides
* VAT and and shipping costs not included. Errors and price changes excepted
